Advertisement
Advertisement

BMRN

BMRN logo

BioMarin Pharmaceuticals Inc

55.27
USD
Sponsored
-0.20
-0.36%
Apr 15, 16:00 UTC -4
Closed
exchange

After-Market

55.77

+0.50
+0.91%

BMRN Earnings Reports

Positive Surprise Ratio

BMRN beat 29 of 41 last estimates.

71%

Next Report

Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$772.41M
/
$0.77
Implied change from Q4 25 (Revenue/ EPS)
-11.68%
/
-420.83%
Implied change from Q1 25 (Revenue/ EPS)
+3.66%
/
-18.95%

BioMarin Pharmaceuticals Inc earnings per share and revenue

On Feb 23, 2026, BMRN reported earnings of -0.24 USD per share (EPS) for Q4 25, missing the estimate of 0.63 USD, resulting in a -137.68% surprise. Revenue reached 874.57 million, compared to an expected 844.44 million, with a 3.57% difference. The market reacted with a -0.48% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 17 analysts forecast an EPS of 0.77 USD, with revenue projected to reach 772.41 million USD, implying an decrease of -420.83% EPS, and decrease of -11.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
logo
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
For Q4 2025, BioMarin Pharmaceuticals Inc reported EPS of -$0.24, missing estimates by -137.68%, and revenue of $874.57M, 3.57% above expectations.
The stock price moved down -0.48%, changed from $62.92 before the earnings release to $62.62 the day after.
The next earning report is scheduled for Apr 29, 2026.
Based on 17 analysts, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.77 and revenue of $772.41M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement